Trials / Recruiting
RecruitingNCT06582771
A Study of Sotorasib in People With Non-Small Cell Lung Cancer
A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sotorasib | Sotorasib 960 mg (8 pills) daily |
Timeline
- Start date
- 2024-08-30
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2024-09-03
- Last updated
- 2026-03-25
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06582771. Inclusion in this directory is not an endorsement.